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Abstract
Introduction: Polo-like kinase-1 (PLK1) is a crucial driver of cell cycle progression and its down-regulation plays an
important checkpoint role in response to DNA damage. Mechanistically, this is mediated by p53 which represses
PLK1 expression through chromatin remodelling. Consistent with this model, cultured cells lacking p53 fail to
repress PLK1 expression. This study examined PLK1 expression, p53 mutation and clinical outcome in breast cancer.
Methods: Immunohistochemistry was performed using antibodies to PLK1, MDM2 and Ki67 on Tissue Micro-Array
(TMA) slides of a cohort of 215 primary breast cancers. The TP53 gene (encoding p53) was sequenced in all tumour
samples. Protein expression scored using the “Quickscore” method was compared with clinical and pathological
data, including survival.
Results: Staining of PLK1 was observed in 11% of primary breast tumours and was significantly associated with the
presence of TP53 mutation (P = 0.0063). Moreover, patients with both PLK1 expression and TP53 mutation showed
a significantly worse survival than those with either PLK1 expression or TP53 mutation alone. There was also a close
association of elevated PLK1 with triple negative tumours, considered to be poor prognosis breast cancers that
generally harbour TP53 mutation. Further association was observed between elevated PLK1 levels and the major
p53 negative regulator, MDM2.
Conclusions: The significant association between elevated PLK1 and TP53 mutation in women with breast cancer
is consistent with escape from repression of PLK1 expression by mutant p53. Tumours expressing elevated PLK1,
but lacking functional p53, may be potential targets for novel anti-PLK1-targeted drugs.
Introduction
Breast cancer remains the most common cancer in
women in the western world. The genetic and molecular
changes underlying the disease are complex. However,
understanding the nature of these changes, and their
potential for therapeutic exploitation, presents enormous
opportunities for individualised approaches to treatment.
To explore these possibilities, there is a need to deter-
mine whether mechanistic events established in cultured
cell systems, which are thought to drive cancer initiation
and/or progression, do indeed underlie the development
of the disease in the patients. The testing of clinical
material, with focus on the presence or absence of key
cancer-associated proteins, should help provide such
supporting evidence and identify relevant new candidate
markers and therapeutic targets.
The p53 tumour suppressor is a short-lived transcrip-
tion factor that plays a critical role in eliminating tumour
cells by coordinating changes in gene expression, leading
to cell cycle arrest, senescence or apoptosis [1-3]. p53
regulates the expression of many genes and, accordingly,
loss of p53 function during tumour development can
have wide-ranging consequences for the pathology of the
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tumour cells [2,4]. Most p53 target genes are actually
repressed, as opposed to transactivated, by p53 [1], with
the outcome that loss of p53 function may lead to dysre-
gulated or even unrestricted levels of oncogenic proteins.
Effective transrepression is, therefore, fundamental to
p53-mediated tumour suppression, and potentially to
clinical outcome. Indeed, mutation of the gene encoding
p53 (TP53) is associated with worse survival in breast
cancer (for example, see [5]).
The protein kinase PLK1 plays a pivotal role in the
maturation of centrosomes, entry into M phase, spindle
formation and cytokinesis [6-8]. Ectopic expression of
PLK1 in cultured cells is oncogenic [9] and, consistent
with this observation, elevated PLK1 levels occur in var-
ious human tumour types [10-20], including breast can-
cers where it is associated with aggressive characteristics,
such as vascular invasion, markers of proliferative activity
and lack of detectable estrogen receptor [17,21]. PLK1 is
down-regulated by p53 as part of the G2/M cell cycle
checkpoint [22-29] and we recently established that this
occurs mainly through p53-dependent repression of
PLK1 expression [30]. Consistent with this observation,
we and others have also shown that p53-null cells are
unable to down-regulate PLK1 levels in response to clini-
cally-relevant genotoxic drugs [26,30]. These data suggest
the possibility that tumours lacking functional p53 are
likely to have dysregulated PLK1 levels and that these, in
turn, may contribute towards the development of malig-
nancy. Recent evidence has also suggested that the viabi-
lity of stressed cells that lack p53 may become dependent
upon PLK1 [26]. Given that PLK1 is widely considered to
be a potential therapeutic target, and that several PLK1
inhibitors are currently undergoing clinical trials [7], tar-
geting of cancers lacking p53 with inhibitors of PLK1
could provide an effective tailored therapeutic strategy.
However, the relationship between PLK1 levels and the
status of the p53 pathway in tumours needs to be
established.
In the present study, we confirm that a proportion of
breast tumours are positive for PLK1 protein expression
as judged by immunohistochemical staining. Strikingly,
we find a statistically significant correlation between the
detection of PLK1 and the acquisition of mutation(s) in
the TP53 gene. Additionally, we find an association
between elevated PLK1 levels and increased levels of the
major p53 negative regulator, MDM2. These findings
support the established in vitro molecular model for
PLK1 repression by p53 [30] and suggest that elevated
PLK1 levels in tumours arise, at least in part, through the
absence of functional p53. To our knowledge, this is the
first demonstration of such an association. From a clini-
cal perspective, we find that patients with TP53 mutation
and detectable PLK1 show reduced survival and are more
likely to have a triple negative genotype. Our data also
highlight the possibility that PLK1-targeted therapy may
be a useful option for tumours lacking functional p53.
Materials and methods
Patients
The cohort used in this study (TMA24) has been
reported previously [31] and comprises 215 unselected
pre- and post-menopausal women (aged 28 to 89; median
62 years) with primary, previously untreated breast can-
cer, who were seen and treated at Tayside University
Hospitals, Scotland from 1997 to 2002. Samples were
obtained at the time of surgery and only where sufficient
cancer material was available. Informed consent was
obtained from each patient prior to tissue acquisition and
before surgery was carried out. Tumour samples from
these patients were constructed on tissue microarray
(TMA) slides as described previously following review of
tissue blocks by specialist breast pathologists [31]; (the
TMAs were constructed from six cores per tumour from
across the tumour, not restricted to the edge of the can-
cer. The values stated are the mean across all six cores).
Ethics approval was given by the Tayside Research and
Ethics Committee (Ref. 07/S1402/90). The PLK1 analysis
was conducted after a median of eight years follow-up
during which some patients had recurred or died. Stan-
dard adjuvant treatment was used: for those patients with
ER-positive tumours tamoxifen or aromatase inhibitors
(for post-menopausal women only) and for node-positive
patients FEC75 chemotherapy; no Herceptin was used on
this cohort.
Western blotting analysis
This was carried out as reported previously [30].
Immunohistochemistry (IHC)
Sections from the TMA block (nominally four microns
thick) were cut onto Superfrost® coated glass slides (VWR
International Ltd., Dublin, Ireland) and dried for one hour
at 60°C before being de-paraffinised in Histoclear
(National Diagnostics, Altanta, GA, USA) and then rehy-
drated through a graded alcohol series. A total of 10 mM
Citric acid buffer was used as the standard microwave-
based antigen retrieval method. Sections were boiled in a
pressure cooker for 10 minutes before being immunos-
tained on a DAKO autostainer (Ely, Cambridgeshire, UK)
using Vectastain® ABC kits (Vector Labs, Burlingame, CA,
USA) according to the manufacturer’s protocol. Briefly,
sections were blocked in normal goat serum containing
10% (v/v) from stock avidin solution (Vector Labs) for
20 minutes followed by a 1 h incubation with Polo-like
Kinase-1 primary antibody (monoclonal antibody 208G4
from Cell Signaling, Boston, MA, USA) at a dilution of 1
in 25 of the material provided by the supplier), including
10% (v/v) from stock biotin solution (Vector Labs) to
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reduce non-specific background staining. Sections were
then incubated with biotinylated anti-rabbit secondary
antibody for 30 minutes followed by Vectastain® Elite
ABC reagent for another 30 minutes. Liquid Diaminoben-
zidine (DAB) (DAKO) was used as a chromogenic agent
for five minutes and sections were counterstained with
Mayer’s haematoxylin. In between each immunostaining
step, slides were washed briefly in Tris buffered saline
(TBS), pH 7.6. Sections known to stain positively were
included in each batch and negative controls were pre-
pared by replacing the primary antibody with TBS buffer.
Antibodies specific for other proteins used in the study
have been reported elsewhere [31].
TP53 mutation status
The mutation status of the TP53 gene was assessed as
described previously in the tissue samples using the
Roche p53 Amplichip research test (Roche Molecular
Systems, Pleasanton, CA, USA); these data and the
detailed methodology are given in reference [32].
Scoring
TMA scoring for PLK1 was carried out by a specialist
breast pathologist (CAP) using a Nikon Eclipse E600 light
microscope (Amstelveen, The Netherlands), Aperio, Scan-
scope XT and Spectrum plus (version 9.1, Vista, CA,
USA). Scoring was semi quantitative using the Quickscore
method [33] for the intensity and proportion of cells
stained for the PLK1 antibody. Scores 0 to 3 indicated the
intensity (0 = no staining, 1 = light staining, 2 = moderate
staining, 3 = strong staining) whilst scores 1 to 6 repre-
sented the proportion of staining (1 = 0 to 4%, 2 = 5 to
20%, 3 = 21 to 40%, 4 = 41 to 60%, 5 = 61 to 80%, 6 = 81
to 100%). Multiplication of each score obtained an overall
result of 0 to 18. Cores taken from a plug of MCF7 cells
were used as a positive control.
Statistics
TMA scoring was analysed to determine appropriate cut-
offs for positive PLK1 or negative staining. The frequency
of each score was plotted as a histogram and passed
through a Dip test to determine the modality of the data.
This resulted in a separation between negative (0 to 3)
and positive (4 to 18) stained cases (Figure 1).
Data analysis
The scoring data were automatically extracted from the
Aperio Digital Pathology system and combined with the
pathology and clinical data from the locally developed
digital pathology database. This resulting data set was
then analysed using an internally developed automated
data analysis system, INSPIRE [34]. For this project,
INSPIRE was employed to exhaustively test the results
of the PLK1 staining against the standard clinical/
pathological outcomes and other staining results held
within the database using the two-sided Fisher’s exact
tests and, where appropriate for survival parameters, the
Kaplan-Meier method. Results were considered signifi-
cant at an a level of 5% (P ≤ 0.05), with anything above
10% (P ≤ 0.10) considered not significant. Results falling
between these two boundaries (0.05 <P ≤ 0.10) were
marked as marginal in the event any warranted further
investigation. The data from INSPIRE were then made
available to the research team via a Comma Separated
Values (CSV) file to allow further manual analysis.
Results that were found to be significant were then re-
analysed manually with SPSS Statistics (Version 17, IBM
Corp., Armonk, NY, USA) to confirm the results found
within INSPIRE. Manual analysis, again using SPSS, was
also used to selectively combine variables, such as PLK
and p53 status.
Survival was calculated from the date of diagnosis until
either the last confirmed hospital visit or the date of death.
An event was only recorded if there was confirmation of a
breast cancer death. All deaths not directly attributable to
breast cancer were censored on the date of death. A
relapse was defined as clinical, radiological or pathological
evidence of disease relapse.
Multivariate analysis
To clarify the results of univariate analysis, PLK1 was
tested for significance within a multivariate environment
using the Cox regression with Backward Conditional
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Figure 1 Histogram of PLK1 staining. Distribution of frequency of
patients against immunohistochemical score of PLK1 staining. Dip
test statistic = 0.087, alpha = 0.036, P < 0.01, identifying a score of 3
as a cut off.
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Results and discussion
Staining of PLK1 in breast tumour samples
The specificity of the antibody for cell staining was con-
firmed by Western blotting analysis of cell extracts carried
out using the monoclonal antibody, 208G4 (Figure 2).
Several different breast cancer-derived cell lines were
examined, and were representative of different breast can-
cer subtypes, p53 wild type/mutant status and the pre-
sence or absence of ERa, PR and HER-2. In each case, a
single band of expected molecular weight 62 kD (as mea-
sured relative to the migration of standards of known
molecular weight) was observed corresponding to full
length PLK1. These data underpin the specificity of the
antibody and validate its application for the immunohisto-
chemical staining of the tumour sections.
The levels of PLK1 staining in the breast tumour sam-
ples varied significantly. A large proportion of samples
showed no detectable staining while those that did gave a
positive signal (23/215; 11% - see Table 1) varied widely
in intensity both from tumour to tumour and, in some
cases, within a tumour section, (that is, a small propor-
tion of cells show intense staining as compared with a
much lower level of staining in the surrounding cells).
Representative examples are shown in Figure 3. These
micrographs also indicate that PLK1 staining, where
identified, was usually observed in both the nucleus and
cytoplasm. Weak or undetectable staining was observed
in normal tissue surrounding the tumours. A correlation
between PLK1 levels and proliferative activity in cycling
cultured cells and in tumours was initially established by
Yuan and colleagues [35]. They also noted especially
strong staining of mitotic cells, an observation that is
consistent with our current knowledge of the cell cycle-
dependent regulation of PLK1 expression (that is, only
low levels of PLK1 are present in cells in the G1 and S
phases as opposed to cells in late G2 and M phase where
the levels rise significantly [36-39]). It is, therefore, possi-
ble that the variation in staining in the tumour samples
could reflect, at least in part, different proliferation rates
of the cells. Consistent with this idea we also note that
PLK1 was associated with Ki67 expression (a marker for
cell proliferation - Table 1). It is also possible that inten-
sely staining cells in any given section are those in G2 or
mitosis. Over and above these proposed mechanisms,
however, it is likely that cancer-associated changes in the
regulation of PLK1 levels additionally contribute to the
differences in levels between different tumour samples
(see below). Such changes could affect the basal level of
expression or the ability to down-regulate PLK1 in
response to environmental changes, independently of
control mediated by the cell cycle.
Relationship of PLK1 expression to TP53 status in breast
cancer patients
There is a significant association between TP53 mutation
status and PLK1 levels (Table 1) such that there is a 3.5-
fold greater likelihood of having detectable PLK1 staining
if the tumour harbours a mutation(s) in the TP53 gene.
We showed recently that PLK1 expression is tightly regu-
lated through p53-mediated transcriptional repression
[30]. The association between PLK1 expression and TP53
mutation is, therefore, consistent with our model [30]
and suggests that elevated PLK1 levels are likely to occur,
at least in part, through the loss of p53 function. We and
others have also shown that p53 is protective against
apoptosis induced by down-regulation of PLK1 in cul-
tured cells [26,30,40]. This observation suggests that
tumour cells retaining wild type p53 function are likely
to be less susceptible to PLK1 inhibitors and, accordingly,
that p53 status is a factor that will have to be taken into
account when considering the use of PLK1 inhibitors as
part of a “personalised medicine” approach. This is espe-
cially significant given that breast cancer patients who
have mutant p53 are less responsive to conventional che-
motherapies [5]. For these patients, PLK1 inhibitors
might be particularly relevant.
Mutation of TP53 can lead not only to inactivation of p53
function but many mutant p53 proteins can interfere with
Figure 2 Anti-PLK1 antibody 208G4 detects only PLK1 in
extracts of several breast cancer-derived cell lines. Cell extracts
were prepared by lysing the cells in SDS-sample buffer and the
proteins were subsequently resolved by SDS-PAGE. Western blotting
analysis reveals a single band of molecular weight 62 kD
corresponding to full length PLK1 in each of the cell extracts.
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wild type p53 function in a dominant-negative manner in
p53 wild type/mutant heterozygotes (reviewed in [41]).
Moreover, certain p53 mutants are thought to acquire new
functional properties that can influence gene expression
levels in a manner that is unaffected by wild type p53.
Many of these mutants have been linked to poor prognosis
in patients, and studies with animal models indicate that
they are likely to promote tumour progression [41,42]. Our
Table 1 Clinico-pathological characteristics of the patients and the odds ratios
Parameter PLK1 Staining P-value Odds Ratio
Pos (N(%)) Neg (N(%))
N 23 (10.7) 192 (89.3) - -
P53 mutational status mutant 12 (5.6) 46 (21.4) 0.0063 3.46
wild type 11 (5.1) 146 (67.9)
unknown 0 0
Histological Grade 1 to 2 2 (1.0) 108 (51.2) < 0.001 14.18
3 21 (10.0) 80 (37.9)
unknown 0 4
Survival dead 9 (4.2) 37 (15.8) 0.02 (Log Rank) 2.318 (HR)
alive 14 (6.5) 155 (73.5)
unknown 0 0
Menopause pre-peri 8 (3.9) 42 (20.2) 0.1861 1.96
post 14 (6.7) 144 (69.2)
unknown 1 6
Lymph Node Status positive 12 (5.7) 90 (42.7) 0.8257 1.19
negative 11 (5.2) 98 (46.5)
unknown 0 4
Size < 2 cm 17 (7.9) 138 (64.2) 1 1.11
>/ = 2 cm 6 (2.8) 54 (25.1)
unknown 0 0
Luminal A positive 7 (3.3) 99 (47.1) 0.075 0.42
negative 15 (7.1) 90 (42.4)
unknown 1 3
Luminal B positive 2 (1.0) 37 (17.6) 0.382 0.41
negative 20 (9.5) 152 (71.9)
unknown 1 3
HER2 positive 5 (2.4) 28 (12.9) 0.344 1.76
negative 17 (8.1) 162 (76.7)
unknown 1 2
ER-alpha positive 12 (5.6) 151 (70.6) 0.0081 3.46
negative 11 (5.1) 40 (18.7)
unknown 0 1
PR positive 10 (4.7) 110 (51.4) 0.266 0.57
negative 13 (6.1) 81 (37.9)
unknown 0 1
Triple negative yes 8 (3.8) 25 (11.9) 0.010 3.8
no 14 (6.7) 164 (77.6)
unknown 1 3
MDM2 positive 10 (4.7) 31 (14.5) 0.004 3.95
negative 13 (6.1) 159 (74.7)
unknown 0 2
Ki67 positive 9 (4.3) 19 (9.1) 0.0004 6.63
negative 12 (5.8) 168 (80.8)
unknown 1 5
The Odds ratio determines the likelihood of showing any given characteristic if the tumour is PLK1 positive as opposed to PLK1 negative. Where numbers in
individual categories do not add up to 215 this is due, in part, to loss of TMA spot data (tumour cut out, folded spots, low cellularity) from individual patients.
*Luminal stains are based on IHC data and are defined as: luminal A, ER+ PR+ HER2- ; and luminal B, ER+ PR- HER2-
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published molecular and cellular analyses suggest that two
commonly-occurring tumour-associated “gain-of-function”
mutants (R175H and R273H respectively) have no effect on
expression from the PLK1 promoter, at least in the context
of promoter-reporter (luciferase) assays [30]. The TP53
mutations identified in the present study show no common
“hotspots” associated with PLK1 expression (data not
shown). As expected, the most common types of the muta-
tions in this cohort were missense mutations, clustered
within exon 5 with a smaller group in exon 9 (Table 2).
While there were insufficient cases in the cohort to provide
unequivocal statistically-supported conclusions, there is a
trend for the mutations in exon 5 to be associated with ele-
vated PLK1 levels (in the tumours expressing high PLK1
levels, 6 mutations out of 12 in total are in exon 5 as com-
pared with 11 in exon 5 out of 46 in total for those tumours
expressing low or undetectable PLK1: Table 2). Exon 5
encodes amino acids 126 to 186 of p53. Future analyses
should test this potential association in a significantly larger
cohort. It will also be interesting to determine whether
Figure 3 Photomicrographs of PLK1 immunohistochemistry from tissue microarray. A and B Grade 3 invasive ductal carcinoma showing a
heterogeneous pattern of nuclear and cytoplasmic staining at low (A) and high (B) power. C and D grade 3 invasive ductal carcinoma showing
similar staining but in fewer cells at low (C) and high (D) power. The staining is highly specific and confined to the carcinoma cells. There is no
staining of vascular, stromal or lymphoid cells.
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mutation of p53 within this region has any additional influ-
ence on PLK1 expression in cultured cells.
An additional issue is that the association between
PLK1 expression and TP53 mutational status is not
absolute; for example, some tumours show elevated
PLK1 levels yet retain wild type TP53 (Table 1). How-
ever, p53 function can be lost not only through muta-
tion of the TP53 gene itself but also through mutation,
or changes in the expression levels, of proteins that reg-
ulate the p53 response. For example, increased expres-
sion of the p53 inhibitors, MDM2 (see below) or
MDM4, is associated with breast cancer development
and is thought to suppress wild type p53 function
[41,42]. It is, therefore, possible that such mechanisms
may contribute to permitting PLK1 levels to rise in the
tumours where mutation of the TP53 gene is absent.
Consistent with this idea we also note a significant asso-
ciation between elevated levels of PLK1 and MDM2
expression (with potential p53 reduction) in our cohort
as a whole (Table 1). However, owing to the small size
of the subset that has both wild type TP53 and elevated
PLK1, we cannot establish any significant association
with MDM2 status. It is also possible that the overall
association between MDM2 and PLK1 could reflect our
previous observation that MDM2 levels may be regu-
lated by PLK1 independently of p53 [30].
Relationship of PLK1 expression to clinical outcome of
breast cancer patients
From a clinical perspective, the data show a striking
association between elevated PLK1 levels in breast can-
cer cells and clinical outcome. PLK1 expression was
associated almost exclusively with tumour grade, being
present predominantly in grade 3 tumours. Moreover,
the survival data (Table 1 and Figure 4A) clearly con-
firm that patients expressing elevated PLK1 expression
show significantly reduced survival. These data are con-
sistent with similar findings reported by others linking
high levels of PLK1 to aggressive disease and poor out-
come [17]. There are no significant associations between
PLK1 expression and menopausal status, lymph node
status or tumour size (Table 1).
By multivariate analysis, in the p53 mutant cancers, only
PLK1 (P = 0.015) and the progesterone receptor (P = 0.04)
were independently associated with survival. For p53 wild
type cancers progesterone receptor (P = 0.041) and size (P
= 0.007) were the only independent variables and for all
patients (no discrimination by mutation status), progester-
one receptor (P < 0.001), tumour grade (P = 0.023), node
positivity (P = 0.011) and size (P = 0.031) were indepen-
dently associated with survival.
There are two additional associations of particular
interest and novelty. Firstly, the occurrence of elevated
PLK1 levels together with TP53 mutation is associated
with poor outcome (Figure 4B), much more so than in
patients harbouring TP53 mutation alone. Interestingly,
patients with tumours that show elevated PLK1 expres-
sion, but retain wild type TP53, have a relatively favour-
able outcome (Figure 4B). This observation indicates
that changes in PLK1 levels may also occur indepen-
dently of regulation by p53 (that is, through changes to
an independent PLK1 regulatory pathway). It also sug-
gests very strongly that p53 is protective against dysre-
gulated PLK1, (which is presumably dysregulated
through p53-independent mechanisms), in the context
of human disease development. The second interesting
Table 2 Mutation spectra for the TP53 gene
Site of Mutation Effect PLK Neg (0-3) PLK1 Pos (4-18)
Exon 4 Deletion 1 0
Exon 5 Missense 11 6
Nonsense 1 0
Exon 6 Missense 5 0
Nonsense 2 1
Exon 7 Deletion 7 2
Exon 8 Missense 9 2
Exon 9 Nonsense 1 0
Exon 10 Deletion 1 0
Missense 2 0
Intron 5 Frame Shift 2 0
Intron 6 Frame Shift 1 1
Intron 9 Frame Shift 1 0
*Exon 5 and 6 Missense, Silent 1 0
*Exon 7, 8 and 9 Missense, Missense, Silent 1 0
46 12
* Tumours where multiple mutations were present
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Figure 4 Kaplan-Meier survival analysis. (A) Data correlating PLK1 staining to breast cancer-specific survival in the cohort TMA24. P = 0.02. (B)
Stratification of the data to show the influence of p53 status on the association between PLK1 staining and breast cancer-specific survival in the
cohort TMA24. P < 0.001. (C) Data correlating PLK1 staining to disease free time in the cohort TMA24. P = 0.072 (D) Stratification of the data to
show the influence of p53 status on the association between PLK1 staining and disease free time in the cohort TMA24. P < 0.001. The number
of patients at 1-, 5- and 10-year time points are shown below each panel.
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feature is the close association of elevated PLK1 with
the triple negative phenotype (Table 1). Triple negative
tumours tend to have mutation(s) of the TP53 gene and
are the most difficult to treat. These data again raise the
possibility that tumours of this phenotype, expressing
elevated PLK1 and harbouring TP53 mutation, may ben-
efit from the use of novel PLK1 inhibitors [7].
The finding that PLK1 expression is associated almost
exclusively with tumour grade (grade 3) could suggest
that PLK1 is a passive feature of grade 3 tumours as
opposed to a change that may drive tumour develop-
ment. To address this issue, grade 3 tumours were re-
examined and demonstrate clearly that PLK1 status was
strongly associated with outcome within the grade 3
tumour subgroup (Figure 5A). This underscores the
adverse influence on survival of having both PLK1 over-
expression and mutant TP53 status within these high
grade cancers (Figure 5B).
Conclusions
Immunohistochemical analysis and DNA sequencing ana-
lysis of 215 primary breast tumours have demonstrated a
striking association between PLK1 expression and TP53
gene mutation. These observations are consistent with our
recently-published molecular model in which wild type
functional p53 behaves as an important transcriptional
repressor of PLK1. Targeting PLK1 in p53 mutant breast
cancer, including poor prognosis, triple negative breast
cancer, may offer therapeutic opportunities.
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survival. P = 0.004. (B) Stratification of the data to show the influence of p53 status on the association between PLK1 staining and breast
cancer-specific survival. P = 0.006. The number of patients at 1-, 5- and 10-year time points are shown below each panel.
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